Multicenter

  • 2012, A Clinical Outcomes study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in subjects with moderate Chronic Obstructive Pulmonary Disease(COPD) and a history of or at Increased risk for cardiovascular Disease. PARELEX Number 110812, 090828 (SUMMIT STUDY)
  • 2012, Protocol SAS115399 : A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionat In the treatment of Adolescent and Adult Subjects wih Asthma (ASMALABA)
  • 2012, Outgoing A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy with Racotumomab Plus Best Support Treatment in Patients with Advanced nonsquamous Non-Small Cell Lung Center
  • 2011, A randomized, parallel-group, open-label, multicentre, 3-month phase IV, efficacy and tolerability study of budesonide/folmoterol(Symbicort® Turbuhaler®160/4.5μg/inhalation, 2 inhalation twice daily) added to tiotropium(Spiriva™18μg/inhalation, 1 inhalation once daily)compared with tiotropium (Spiriva®18μg/inhalation, 1 inhalation once daily) alone in severe chronic obstructive pulmonary disease (COPD) patients. (SECURE I)
  • 2008, Cross sectional study of prevalence and distribution of cigarette smoking habits in Indonesian male hospital patients with non-tobacco-related admissions diagnoses
  • 2006, An open label, randomized, parallel group, multicentre, phase III study to assess efficacy, safety and tolerability of gefitinib (IRESSATM) (250 mg tablet) versus carboplatin/paclittaxel doublet chemotheraphy as first-line treatment in selected patients with advanced (stage IIIB or IV) non – small cell lung cancer (NSCLC) in Asia (IPASS)
  • 2004, Efficacy and safety of Symbicort “Turbuhaler” 160/4.5 μg/Inhalation, two inhalations twice daily plus as-needed compared with seretideTM DIiskus TM 50/500 μg/inhalation, one inhalation twice daily plus terbutalin Turbuhaler 0,4 mg/inhalation as-needded-a 6-month, randomised,double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma (AHEAD)